Literature DB >> 24834770

Assessment of severity and quality of life in chronic urticaria.

I Jáuregui, F J Ortiz de Frutos, M Ferrer, A Giménez-Arnau, J Sastre, J Bartra, M Labrador, J F Silvestre, A Valero.   

Abstract

Chronic urticaria (CU) is very prevalent in the general population and, despite its low mortality, can have devastating effects on the quality of life (QoL) of those who experience it.Therefore, consensus documents on its classification, diagnosis, and treatment have become a necessity. The intensity of urticaria is currently evaluated using indices such as the Urticaria Activity Score and visual analog scales to assess itch or the degree of itch associated with the use of antihistamines. QoL is evaluated using various generic questionnaires and specific tools for skin disease and for CU. In recent years, attempts have been made to combine these evaluations to create a specific tool that would enable us to simultaneously evaluate the severity of the condition and the impact of symptoms on QoL. One such tool is the Urticaria Severity Score, which also allows us to compare global changes brought about by different treatments.

Entities:  

Mesh:

Year:  2014        PMID: 24834770

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  11 in total

1.  Chronic Idiopathic Urticaria: Systemic Complaints and Their Relationship with Disease and Immune Measures.

Authors:  Judy C Doong; Kris Chichester; Eric T Oliver; Lawrence B Schwartz; Sarbjit S Saini
Journal:  J Allergy Clin Immunol Pract       Date:  2017-03-14

2.  Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.

Authors:  Ciro Romano; Ausilia Sellitto; Umberto De Fanis; Antonella Balestrieri; Alfonso Savoia; Salvatore Abbadessa; Corrado Astarita; Giacomo Lucivero
Journal:  Clin Drug Investig       Date:  2015-03       Impact factor: 2.859

Review 3.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

Review 4.  Management of urticaria: not too complicated, not too simple.

Authors:  M Ferrer; J Bartra; A Giménez-Arnau; I Jauregui; M Labrador-Horrillo; J Ortiz de Frutos; J F Silvestre; J Sastre; M Velasco; A Valero
Journal:  Clin Exp Allergy       Date:  2015-04       Impact factor: 5.018

5.  Chronic urticaria in most patients is poorly controlled. Results of the development, validation, and real life application of the arabic urticaria control test.

Authors:  Carla Irani; Souheil Hallit; Karsten Weller; Marcus Maurer; Carla El Haber; Pascale Salameh
Journal:  Saudi Med J       Date:  2017-12       Impact factor: 1.484

6.  Sense of coherence as a protective factor in chronic urticaria.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Pietrzak; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

7.  Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.

Authors:  Eva Serrano-Candelas; Rubén Martínez-Aranguren; Olga Vega; Gabriel Gastaminza; Joan Bartra; Maria Teresa Audicana; Jorge M Núñez-Córdoba; Jaime Algorta; Antonio Valero; Margarita Martin; Marta Ferrer
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

Review 8.  Profile of omalizumab in the treatment of chronic spontaneous urticaria.

Authors:  Moises Labrador-Horrillo; Marta Ferrer
Journal:  Drug Des Devel Ther       Date:  2015-08-25       Impact factor: 4.162

9.  Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT).

Authors:  Kanokvalai Kulthanan; Leena Chularojanamontri; Papapit Tuchinda; Chuda Rujitharanawong; Marcus Maurer; Karsten Weller
Journal:  Health Qual Life Outcomes       Date:  2016-04-14       Impact factor: 3.186

10.  Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria.

Authors:  A Y Finlay; A P Kaplan; L A Beck; E N Antonova; M-M Balp; J Zazzali; S Khalil; M Maurer
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-07-19       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.